1.
Adameova, A., Shah, A. K. and Dhalla, N. S. 2020. Role of
oxidative stress in the genesis of ventricular arrhy thmias. Int.
J. Mol. Sci. 21: 4200.
2.
Andersen, S., Nielsen-Kudsk, J. E., Vonk Noordegraaf, A. and
De Man, F. S. 2019. Right ventricular fibrosis: A
pathophysiological factor in pulmonary hypertension?
Circulation. 139: 269–285.
3.
Benjamin, E. J., Muntner, P., Alonso, A., Bittencourt, M. S.,
Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang,
A. R., Cheng, S., Das, S. R., Delling, F. N., Djousse, L.,
Elkind, M. S. V., Ferguson, J. F., Fornage, M., Jordan, L. C.,
Khan, S. S., Kissela, B. M., Knutson, K. L., Kwan, T. W.,
Lackland, D. T., Lewis, T. T., Lichtman, J. H., Longenecker,
C. T., Loop, M. S., Lutsey, P. L., Martin, S. S., Matsushita,
K., Moran, A. E., Mussolino, M. E., O’Flaherty, M., Pandey,
A., Perak, A. M., Rosamond, W. D., Roth, G. A., Sampson, U.
K. A., Satou, G. M., Schroeder, E. B., Shah, S. H., Spartano,
N. L., Stokes, A., Tirschwell, D. L., Tsao, C. W., Turakhia, M.
P., VanWagner, L. B., Wilkins, J. T., Wong, S. S. and Virani,
S. S. 2019. Heart disease and stroke statistics -2019 update: A
report from the American Heart Association. Circulation. 139:
e56–e66.
171
4.
van den Borne, S. W. M., Diez, J., Blankesteijn, W. M.,
Verjans, J., Hofstra, L. and Narula, J. 2010. Myocardial
remodeling after infarction: the role of myofibroblasts. Nat.
Rev. Cardiol. 7: 30–37.
5.
Boucherat, O., Vitry, G., Trinh, I., Paulin, R., Provencher, S.
and Bonnet, S. 2017. The cancer theory of pulmonary arterial
hypertension. Pulm. Circ. 7: 285–299.
6.
Brown, N. F. and Marshall, J. F. 2019. Integrin -mediated
TGF activation modulates the tumour microenviro nment.
Cancers (Basel). 11: 1221.
7.
Campo, A., Mathai, S. C., Le Pavec, J., Zaiman, A. L.,
Hummers, L. K., Boyce, D., Housten, T., Lechtzin, N., Chami,
H., Girgis, R. E. and Hassoun, P. M. 2011. Outcomes of
hospitalisation for right heart failure in pulmo nary arterial
hypertension. Eur. Respir. J. 38: 359–367.
8.
Chang, C. J., Hsu, H. C., Ho, W. J., Chang, G. J., Pang, J. H.
S., Chen, W. J., Huang, C. C. and Lai, Y. J. 2019. Cathepsin S
promotes the development of pulmonary arterial hypertension.
Am. J. Physiol. Lung Cell. Mol. Physiol. 317: L1–L13.
9.
Chen, H., Wang, J., Xiang, M. X., Lin, Y., He, A., Jin, C. N.,
Guan, J., Sukhova, G. K., Libby, P., Wang, J. A. and Shi, G.
P. 2013. Cathepsin S-mediated fibroblast trans-differentiation
contributes to left ventricular remodelling after myocardial
infarction. Cardiovasc. Res. 100: 84–94.
172
10.
Cheng, K. C., Li, Y., Chang, W. T., Chen, Z. C., Cheng, J. T.
and Tsai, C. C. 2019. Ubiquitin-protein ligase E3a (UBE3A) as
a new biomarker of cardiac hypertrophy in cell models. J.
Food Drug Anal. 27: 355–364.
11.
Cheng, X. W., Shi, G. P., Kuzuya, M., Sasaki, T., Okumura, K.
and Murohara, T. 2012. Role for cysteine protease cathepsins
in heart disease: Focus on biology and mechanisms with
clinical implication. Circulation. 125: 1551–1562.
12.
Cowden Dahl, K. D., Robertson, S. E., Weaver, V. M. and
Simon, M. C. 2005. Hypoxia-inducible factor regulates v3
integrin cell surface expression. Mol. Biol. Cell. 16: 1901–
1912.
13.
Damico, R., Kolb, T. M., Valera, L., Wang, L., Housten, T.,
Tedford, R. J., Kass, D. A., Rafaels, N., Gao, L., Barnes, K.
C., Benza, R. L., Rand, J. L., Hamid, R., Loyd, J. E., Robbins,
I. M., Hemnes, A. R., Chung, W. K., Austin, E. D., Drummond,
M. B., Mathai, S. C. and Hassoun, P. M. 2015. Serum
endostatin is a genetically determined predictor of survival in
pulmonary arterial hypertension. Am. J. Respir. Crit. Care
Med. 191: 208–218.
14.
Davis, G. E., Bayless, K. J., Davis, M. J. and Meininger, G. A.
2000. Regulation of tissue injury responses by the exposure of
matricryptic sites within extracellular matrix molecules. Am.
J. Pathol. 156: 1489–1498.
173
15.
Diehl, K. H., Hull, R., Morton, D., Pfister, R.,
Rabemampianina, Y., Smith, D., Vidal, J. M. and Van De
Vorstenbosch, C. 2001. A good practice guide to the
administration of substances and removal of blood, including
routes and volumes. J. Appl. Toxicol. 21: 15–23.
16.
Dodo, K., Shimizu, T., Sasamori, J., Aihara, K., Terayama, N.,
Nakao, S., Iuchi, K., Takahashi, M. and Sodeoka, M. 2018.
Indolylmaleimide derivative IM -17 shows cardioprotective
effects in ischemia-reperfusion injury. ACS Med. Chem. Lett.
9: 182–187.
17.
Finegold, J. A., Asaria, P. and Francis, D. P. 2013. Mortality
from ischaemic heart disease by country, region, and age:
Statistics from World Health Organisation and United Nations.
Int. J. Cardiol. 168: 934–945.
18.
Frey, N., Katus, H. A., Olson, E. N. and Hill, J. A. 2004.
Hypertrophy of the heart: A new therapeutic target?
Circulation. 109: 1580–1589.
19.
Fu, Y., Tang, H., Huang, Y., Song, N. and Luo, Y. 2009.
Unraveling the mysteries of endostatin. IUBMB Life. 61: 613–
626.
20.
Givvimani, S., Kundu, S., Narayanan, N., Armaghan, F.,
Qipshidze, N., Pushpakumar, S., Vacek, T. P. and Tyagi, S. C.
2013. TIMP-2 mutant decreases MMP-2 activity and augments
pressure overload induced LV dysfunction and heart failure.
174
Arch. Physiol. Biochem. 119: 65–74.
21.
Gomez-Arroyo, J. G., Farkas, L., Alhussaini, A. A., Farkas,
D., Kraskauskas, D., Voelkel, N. F. and Bogaard, H. J. 2012.
The monocrotaline model of pulmonary hypertension in
perspective. Am. J. Physiol. Lung Cell. Mol. Physiol. 302:
L363–L369.
22.
Gouya, G., Siller-Matula, J. M., Fritzer-Szekeres, M.,
Neuhold, S., Storka, A., Neuhofer, L. M., Clodi, M.,
Hülsmann, M., Pacher, R. and Wolzt, M. 2014. Association of
endostatin with mortality in patients with chronic heart
failure. Eur. J. Clin. Invest. 44: 125–135.
23.
Granger, D. N. and Kvietys, P. R. 2015. Reperfusion injury
and reactive oxygen species: The evolution of a concept.
Redox Biol. 6: 524–551.
24.
Hammerman, H., Kloner, R. A., Schoen, F. J., Brown, E. J.,
Hale, S. and Braunwald, E. 1983. Indomethacin -induced scar
thinning after experimental myocardial infarction. Circulation.
67: 1290–1295.
25.
Han, Q., Fu, Y., Zhou, H., He, Y. and Luo, Y. 2007.
Contributions of Zn(II)-binding to the structural stability of
endostatin. FEBS Lett. 581: 3027–3032.
26.
Harston, R. K. and Kuppuswamy, D. 2011. Integrins are the
necessary links to hypertrophic growth in cardiomyocytes. J.
Signal Transduct. 2011: 521742.
175
27.
Hasegawa, H., Naito, I., Nakano, K., Momota, R., Nishida, K.,
Taguchi, T., Sado, Y., Ninomiya, Y. and Ohtsuka, A. 2007.
The distributions of type IV collagen chains in basement
membranes of human epidermis and skin appendages. Arch.
Histol. Cytol. 70: 255–265.
28.
Hausenloy, D. J. and Yellon, D. M. 2013. Myocardial
ischemia-reperfusion injury: a neglected therapeutic target. J.
Clin. Invest. 123: 92–100.
29.
He, X. P., Li, Z. S., Zhu, R. M., Tu, Z. X., Gao, J., Pan, X.,
Gong, Y. F., Jin, J., Man, X. H., Wu, H. Y. and Xu, A. F.
2006. Effects of recombinant human canstatin protein in the
treatment of pancreatic cancer. World J. Gastroenterol. 12:
6652–6657.
30.
Hinenoya, N., Naito, I., Momota, R., Sado, Y., Kumagishi, K.,
Ninomiya, Y. and Ohtsuka, A. 2008. Type IV collagen alpha
chains of the basement membrane in the rat bronchioalveolar
transitional segment. Arch. Histol. Cytol. 71: 185–194.
31.
Honoré, S., Kovacic, H., Pichard, V., Briand, C. and Rognoni,
J. B. 2003. 21-integrin signaling by itself controls G1/S
transition in a human adenocarcinoma cell line (Caco -2):
Implication of NADPH oxidase-dependent production of ROS.
Exp. Cell Res. 285: 59–71.
32.
Huang, J., Li, X., Shi, X., Zhu, M., Wang, J., Huang, S.,
Huang, X., Wang, H., Li, L., Deng, H., Zhou, Y., Mao, J.,
176
Long, Z., Ma, Z., Ye, W., Pan, J., Xi, X. and Jin, J. 2019.
Platelet integrin IIb3: Signal transduction, regulation, and
its therapeutic targeting. J. Hematol. Oncol. 12: 26.
33.
Hudson, B. G., Stephen, T. and Tryggvasonll, K. 1993. Type
IV collagen: structure, gene organization, and role in human
diseases. Molecular basis of Goodpasture and Alport
syndromes and diffuse leiomyomatosis. J. Biol. Chem. 268:
26033–26036.
34.
Imoto, K., Hirakawa, M., Okada, M. and Yamawaki, H. 2018.
Canstatin modulates L-type calcium channel activity in rat
ventricular cardiomyocytes. Biochem. Biophys. Res. Commun.
499: 954–959.
35.
Imoto, K., Kumatani, S., Okada, M. and Yamawaki, H. 2016.
Endostatin is protective against monocrotaline-induced right
heart disease through the inhibition of T -type Ca2+channel.
Pflügers Arch. 468: 1259–1270.
36.
Imoto, K., Okada, M. and Yamawaki, H. 2018. Periostin
mediates right ventricular failure through induction of
inducible nitric oxide synthase expression in right ventricular
fibroblasts from monocrotaline-induced pulmonary arterial
hypertensive rats. Int. J. Mol. Sci. 20: 62.
37.
Imoto, K., Okada, M. and Yamawaki, H. 2017. Expression
profile of matricellular proteins in hypertrophied ri ght
ventricle of monocrotaline-induced pulmonary hypertensive
177
rats. J. Vet. Med. Sci. 79: 1096–1102.
38.
Isobe, K., Kuba, K., Maejima, Y., Suzuki, J., Kubota, S. and
Isobe, M. 2010. Inhibition of endostatin/collagen XVIII
deteriorates left ventricular remodeling and heart failure in
rat myocardial infarction model. Circ. J. 74: 109–119.
39.
Iwanaga, K., Murata, T., Okada, M., Hori, M. and Ozaki, H.
2009. Carbachol induces Ca2+-dependent contraction via
muscarinic M2 and M3 receptors in rat intestinal subepi thelial
myofibroblasts. J. Pharmacol. Sci. 110: 306–314.
40.
Jeong, E. M., Liu, M., Sturdy, M., Gao, G., Varghese, S. T.,
Sovari, A. A. and Dudley Jr., S. C. 2012. Metabolic stress,
reactive oxygen species, and arrhythmia. J. Mol. Cell.
Cardiol. 52: 454–463.
41.
Kamphaus, G. D., Colorado, P. C., Panka, D. J., Hopfer, H.,
Ramchandran, R., Torre, A., Maeshima, Y., Mier, J. W.,
Sukhatme, V. P. and Kalluri, R. 2000. Canstatin, a novel
matrix-derived inhibitor of angiogenesis and tumor growth. J.
Biol. Chem. 275: 1209–1215.
42.
Kanazawa, H., Imoto, K., Okada, M. and Yamawaki, H. 2017.
Canstatin inhibits hypoxia-induced apoptosis through
activation of integrin/focal adhesion kinase/Akt signaling
pathway in H9c2 cardiomyoblasts. PLoS One. 12: e0173051.
43.
Khakoo, A. Y., Yurgin, N. R., Eisenberg, P. R. and Fonarow,
G. C. 2019. Overcoming barriers to development of novel
178
therapies for cardiovascular disease: Insights from the
oncology drug development experience. JACC Basic to Transl.
Sci. 4: 269–274.
44.
Khoshnoodi, J., Pedchenko, V. and Hudson, B. G. 2008.
Mammalian collagen IV. Microsc. Res. Tech. 71: 357–370.
45.
Kim, E. Y., Roshanravan, H. and Dryer, S. E. 2015. Syndecan 4 ectodomain evokes mobilization of podocyte TRPC6 channels
and their associated pathways: An essential role for integrin
signaling. Biochim. Biophys. Acta. 1853: 2610–2620.
46.
Kistamás, K., Veress, R., Horváth, B., Bányász, T., Nánási, P.
P. and Eisner, D. A. 2020. Calcium handling defects and
cardiac arrhythmia syndromes. Front. Pharmacol. 11: 72.
47.
児玉
逸雄
班 長 [2008年 度 合 同 研 究 班 (日 本 循 環 器 学 会 、 日 本
小児循環器学会、日本心臓病学会、日本心電学会、日本不
整 脈 学 会 )報 告 ] 2009. 不 整 脈 薬 物 治 療 に 関 す る ガ イ ド ラ イ ン
(2009年 改 訂 版 ).
48.
厚 生 労 働 省 . 2018. 平 成 30年 度
国民医療費の概況.
https://www.mhlw.go.jp/toukei/saikin/hw/k iryohi/18/dl/kekka.pdf. 2020/12/24 閲 覧
49.
厚 生 労 働 省 . 2019. 令 和 元 年 (2019) 人 口 動 態 統 計 月 報 年 計
(概 数 )の 概 況 .
https://www.mhlw.go.jp/toukei/saikin/hw/jinkou/geppo/nengai1
9/dl/kekka.pdf. 2020/12/24 閲 覧
50.
Kuwahara, K., Wang, Y., McAnally, J., Richardson, J. A.,
179
Bassel-Duby, R., Hill, J. A. and Olson, E. N. 2006. TRPC6
fulfills a calcineurin signaling circuit during pathologic
cardiac remodeling. J. Clin. Invest. 116: 3114–3126.
51.
Lal, H., Guleria, R., Foster, D., Lu, G., Watson, L., Sanghi,
S., Smith, M. and Dostal, D. 2007. Integrins: Novel
therapeutic targets for cardiovascular diseases. Cardiovasc.
Hematol. Agents Med. Chem. 5: 109–132.
52.
Landstrom P, A., Dobrev, D. and Wehren s HT, X. 2017.
Calcium signaling and cardiac arrhythmias. Circ. Res. 120:
1969–1993.
53.
Lee, T. Y., Tjin Tham Sjin, R. M., Movahedi, S., Ahmed, B.,
Pravda, E. A., Lo, K. M., Gillies, S. D., Folkman, J. and
Javaherian, K. 2008. Linking antibody Fc domain t o endostatin
significantly improves endostatin half-life and efficacy. Clin.
Cancer Res. 14: 1487–1493.
54.
Li, Q., Lin, X., Yang, X. and Chang, J. 2010. NFATc4 is
negatively regulated in miR-133a-mediated cardiomyocyte
hypertrophic repression. Am. J. Physiol. Circ. Physiol. 298:
H1340–H1347.
55.
Liang, R., Xie, H. Y., Lin, Y., Li, Q., Yuan, C. L., Liu, Z. H.
and Li, Y. Q. 2016. Intraperitoneal perfusion therapy of
endostar combined with platinum chemotherapy for malignant
serous effusions: A meta-analysis. Asian Pacific J. Cancer
Prev. 16: 8637–8644.
180
56.
Lu, H. R., Yang, P., Remeysen, P., Saels, A., Dai, D. Z. and
De Clerck, F. 1999. Ischemia/reperfusion -induced arrhythmias
in anaesthetized rats: A role of Na + and Ca2+ influx. Eur. J.
Pharmacol. 365: 233–239.
57.
Luo, Y. Q., Li-JuanYao, Zhao, L., Sun, A. Y., Dong, H., Du, J.
P., Wu, S. Z. and Hu, W. 2010. Development of an ELISA for
quantification of tumstatin in serum samples and tissue
extracts of patients with lung carcinoma. Clin. Chim. Acta.
411: 510–515.
58.
Ma, Y., Brás, L. E. D. C., Toba, H., Iyer, R. P. and Lindsey,
M. L. 2014. Myofibroblasts and the extracellular matrix
network in post-myocardial infarction cardiac remodeling.
Pflügers Arch. 466: 1113–1127.
59.
Magnon, C., Galaup, A., Mullan, B., Ro uffiac, V., Bidart, J.
M., Griscelli, F., Opolon, P. and Perricaudet, M. 2005.
Canstatin acts on endothelial and tumor cells via
mitochondrial damage initiated through interaction with v3
and v5 integrins. Cancer Res. 65: 4353–4361.
60.
Martínez-Martínez, S., Lozano-Vidal, N., López-Maderuelo, M.
D., Jiménez-Borreguero, L. J., Armesilla, Á. L. and Redondo,
J. M. 2019. Cardiomyocyte calcineurin is required for the
onset and progression of cardiac hypertrophy and fibrosis in
adult mice. FEBS J. 286: 46–65.
61.
Matsubara, H. and Ogawa, A. 2014. Treatment of
181
idiopathic/hereditary pulmonary arterial hypertension. J.
Cardiol. 64: 243–249.
62.
Molkentin, J. D., Lu, J. R., Antos, C. L., Markham, B.,
Richardson, J., Robbins, J., Grant, S. R. and Ol son, E. N.
1998. A calcineurin-dependent transcriptional pathway for
cardiac hypertrophy. Cell. 93: 215–228.
63.
Monboisse, J. C., Oudart, J. B., Ramont, L., Brassart -Pasco, S.
and Maquart, F. X. 2014. Matrikines from basement membrane
collagens: A new anti-cancer strategy. Biochim. Biophys. Acta.
1840: 2589–2598.
64.
Mukohda, M., Morita, T., Okada, M., Hara, Y. and Yamawaki,
H. 2012. Long-term methylglyoxal treatment impairs smooth
muscle contractility in organ-cultured rat mesenteric artery.
Pharmacol. Res. 65: 91–99.
65.
Murakami, M., Kusachi, S., Nakahama, M., Naito , I.,
Murakami, T., Doi, M., Kondo, J., Higashi, T., Ninomiya, Y.
and Tsuji, T. 1998. Expression of the 1 and 2 chains of type
IV collagen in the infarct zone of rat myocardial infarction. J.
Mol. Cell. Cardiol. 30: 1191–1202.
66.
Naranjo, M., Lo, K. B., Mezue, K. and Rangaswami, J. 2019.
Effects of pulmonary hypertension and right ventricular
function in short and long-term kidney function. Curr.
Cardiol. Rev. 15: 3–11.
67.
Neri, M., Riezzo, I., Pascale, N., Pomara, C. and Turillazzi, E.
182
2017. Ischemia/reperfusion injury following acute myocardial
infarction: A critical issue for clinicians and forensic
pathologists. Mediators Inflamm. 2017: 7018393.
68.
van Nieuwenhoven, F. A. and Turner, N. A. 2013. The role of
cardiac fibroblasts in the transition from inflammation to
fibrosis following myocardial infarction. Vascul. Pharmacol.
58: 182–188.
69.
Nieves-Cintrón, M., Hirenallur-Shanthappa, D., Nygren, P. J.,
Hinke, S. A., Dell’Acqua, M. L., Langeberg, L. K., Navedo,
M., Santana, L. F. and Scott, J. D. 2016. AKAP150
participates in calcineurin/NFAT activation during the down regulation of voltage-gated K+ currents in ventricular
myocytes following myocardial infarction. Cell. Signal. 28:
733–740.
70.
Nikolova, A., Ablasser, K., Ballmoos, M. C. W. Von, Poutia s,
D., Kaza, E., Mcgowan, F. X., Moses, M. A., Nido, P. J. and
Friehs, I. 2012. Endogenous angiogenesis inhibitors prevent
adaptive capillary growth in left ventricular pressure overload
hypertrophy. Ann. Thorac. Surg. 94: 1509–1517.
71.
Nishimoto, T., Mlakar, L., Takihara, T. and Feghali -bostwick,
C. 2015. An endostatin-derived peptide orally exerts antifibrotic activity in a murine pulmonary fibrosis model. Int.
Immunopharmacol. 28: 1102–1105.
72.
Okada, H., Lai, N. C., Kawaraguchi, Y., Liao, P., Copps, J.,
183
Sugano, Y., Okada-Maeda, S., Banerjee, I., Schilling, J. M.,
Gingras, A. R., Asfaw, E. K., Suarez, J., Kang, S. M., Perkins,
G. A., Au, C. G., Israeli-Rosenberg, S., Manso, A. M., Liu, Z.,
Milner, D. J., Kaufman, S. J., Patel, H. H., Roth, D. M.,
Hammond, H. K., Taylor, S. S., Dillmann, W. H., Goldhaber, J.
I. and Ross, R. S. 2013. Integrins protect cardiomyocytes from
ischemia/reperfusion injury. J. Clin. Invest. 123: 4294–4308.
73.
Okada, M., Morioka, S., Kanazawa, H. and Yamawaki, H . 2016.
Canstatin inhibits isoproterenol -induced apoptosis through
preserving mitochondrial morphology in differentiated H9c2
cardiomyoblasts. Apoptosis. 21: 887–895.
74.
Okada, M., Murata, N. and Yamawaki, H. 2017. Canstatin
stimulates migration of rat cardiac fibroblasts via secretion of
matrix metalloproteinase-2. Am. J. Physiol. Cell Physiol. 312:
C199–C208.
75.
Östman-Smith, I. 1981. Cardiac sympathetic nerves as the
final common pathway in the induction of adaptive cardiac
hypertrophy. Clin. Sci. 61: 265–272.
76.
Otani, K., Yokoya, M., Kodama, T., Hori, K., Matsumoto, K.,
Okada, M. and Yamawaki, H. 2018. Plasma exosomes regulate
systemic blood pressure in rats. Biochem. Biophys. Res.
Commun. 503: 776–783.
77.
Ozer, M. K., Sahna, E., Birincioglu, M. and Acet, A. 2002.
Effects of captopril and losartan on myocardial ischemia -
184
reperfusion induced arrhythmias and necrosis in rats.
Pharmacol. Res. 45: 257–263.
78.
Page, R. L., Joglar, J. A., Caldwell, M. A., Calkins, H., Conti,
J. B., Deal, B. J., Estes, N. A. M., Field, M. E., Goldberger,
Z. D., Hammill, S. C., Indik, J. H., Lindsay, B. D., Olshansky,
B., Russo, A. M., Shen, W. K., Tracy, C. M. and Al -Khatib, S.
M. 2016. 2015 ACC/AHA/HRS guideline for the management of
adult patients with supraventricular tachycardia: A report of
the American College of Cardiology/American Heart
Association Task Force on Clinical Practice Guidelines and the
Heart Rhythm Society. Circulation. 133: e506–e574.
79.
Parekh, A., Sandulache, V. C., Singh, T., Cetin, S., Sacks, M.
S., Dohar, J. E. and Hebda, P. A. 2009. Prostaglandin E 2
differentially regulates contraction and structural
reorganization of anchored collagen gels by human adult and
fetal dermal fibroblasts. Wound Repair Regen. 17: 88–98.
80.
Park, J. Y., Pillinger, M. H. and Abramson, S. B. 2006.
Prostaglandin E2 synthesis and secretion: The role of PGE 2
synthases. Clin. Immunol. 119: 229–240.
81.
Perrucci, G. L., Barbagallo, V. A., Corlianò, M., Tosi, D.,
Santoro, R., Nigro, P., Poggio, P., Bulfamante, G., Lombardi,
F. and Pompilio, G. 2018. Integrin v5 in vitro inhibition
limits pro-fibrotic response in cardiac fibroblasts of
spontaneously hypertensive rats. J. Transl. Med. 16: 352.
185
82.
Pezzuto, B., Badagliacca, R., Poscia, R., Ghio, S., D’Alto, M.,
Vitulo, P., Mulè, M., Albera, C., Volterrani, M., Fedele, F.
and Vizza, C. D. 2015. Circulating biomarkers in pulmonary
arterial hypertension: Update and future direction. J. Hear.
Lung Transplant. 34: 282–305.
83.
Power, A. S., Hickey, A. J., Crossman, D. J., Loiselle, D. S.
and Ward, M. L. 2018. Calcium mishandling impairs
contraction in right ventricular hypertrophy prior to overt
heart failure. Pflügers Arch. 470: 1115–1126.
84.
Priori, S. G., Blomström-Lundqvist, C., Mazzanti, A., Bloma,
N., Borggrefe, M., Camm, J., Elliott, P. M., Fitzsimons, D.,
Hatala, R., Hindricks, G., Kirchhof, P., Kjeldsen, K., Kuck, K.
H., Hernandez-Madrid, A., Nikolaou, N., Norekvål, T. M.,
Spaulding, C., Van Veldhuisen, D. J., Kolh, P., Lip, G. Y. H.,
Agewall, S., Barón-Esquivias, G., Boriani, G., Budts, W.,
Bueno, H., Capodanno, D., Carerj, S., Crespo -Leiro, M. G.,
Czerny, M., Deaton, C., Dobrev, D., Erol, Ç., Galderisi, M.,
Gorenek, B., Kriebel, T., Lambiase, P., Lancellotti, P., Lane,
D. A., Lang, I., Manolis, A. J., Morais, J., Moreno, J.,
Piepoli, M. F., Rutten, F. H., Sredniawa, B., Zamorano, J. L.
and Zannad, F. 2015. 2015 ESC Guidelines for the management
of patients with ventricular arrhythmias and the prevention of
sudden cardiac death: The task force for the management of
patients with ventricular arrhythmias and the prevention of
186
sudden cardiac death of the Europe. Europace. 17: 1601–1687.
85.
Rai, V., Sharma, P., Agrawal, S. and Agrawal, D. K. 2017.
Relevance of mouse models of cardiac fibrosis and
hypertrophy in cardiac research. Mol. Cell. Biochem. 424:
123–145.
86.
Rebustini, I. T., Myers, C., Lassiter, K. S., Surmak, A.,
Szabova, L., Holmbeck, K., Pedchenko, V., Hudson, B. G. and
Hoffman, M. P. 2009. MT2-MMP-dependent release of collagen
IV NC1 domains regulates submandibular gland branching
morphogenesis. Dev. Cell. 17: 482–493.
87.
Ren, J., Avery, J., Zhao, H., Schneider, J. G., Ross, F. P . and
Muslin, A. J. 2007. 3 integrin deficiency promotes cardiac
hypertrophy and inflammation. J. Mol. Cell. Cardiol. 42: 367–
377.
88.
Ricard-blum, S. and Salza, R. 2014. Matricryptins and
matrikines : biologically active fragments of the extracellular
matrix. Exp. Dermatol. 23: 457–463.
89.
Rienks, M., Papageorgiou, A. P., Frangogiannis, N. G. and
Heymans, S. 2014. Myocardial extracellular matrix: An ever changing and diverse entity. Circ. Res. 114: 872–888.
90.
Ruwhof, C. and Van Der Laarse, A. 2000. Mec hanical stressinduced cardiac hypertrophy: mechanisms and signal
transduction pathways. Cardiovasc. Res. 47: 23–37.
91.
Sabourin, J., Boet, A., Rucker-Martin, C., Lambert, M.,
187
Gomez, A. M., Benitah, J. P., Perros, F., Humbert, M. and
Antigny, F. 2018. Ca2+ handling remodeling and
STIM1L/Orai1/TRPC1/TRPC4 upregulation in monocrotaline induced right ventricular hypertrophy. J. Mol. Cell. Cardiol.
118: 208–224.
92.
Sado, Y., Inoue, S., Tomono, Y. and Omori, H. 2006.
Lymphocytes from enlarged iliac lymph nodes as fusion
partners for the production of monoclonal antibodies after a
single tail base immunization attempt. Acta Histochem.
Cytochem. 39: 89–94.
93.
Sakamoto, Y., Kameshima, S., Kakuda, C., Okamura, Y.,
Kodama, T., Okada, M. and Yamawaki, H. 2017. Visceral
adipose tissue-derived serine protease inhibitor prevents the
development of monocrotaline-induced pulmonary arterial
hypertension in rats. Pflügers Arch. 469: 1425–1432.
94.
Samak, M., Fatullayev, J., Sabashnikov, A., Zeriouh, M.,
Schmack, B., Farag, M., Popov, A. F., Dohmen, P. M., Choi,
Y. H., Wahlers, T. and Weymann, A. 2016. Cardiac
hypertrophy: An introduction to molecular and cellular basis.
Med. Sci. Monit. Basic Res. 22: 75–79.
95.
Sanchez-Alonso, J. L., Bhargava, A., O’Hara, T., Glukh ov, A.
V, Schobesberger, S., Bhogal, N., Sikkel, M. B., Mansfield,
C., Korchev, Y. E., Lyon, A. R., Punjabi, P. P., Nikolaev, V.
O., Trayanova, N. A. and Gorelik, J. 2016. Microdomain -
188
specific modulation of L-type calcium channels leads to
triggered ventricular arrhythmia in heart failure. Circ. Res.
119: 944–955.
96.
Schumann, C., Lepper, P. M., Frank, H., Schneiderbauer, R.,
Wibmer, T., Kropf, C., Stoiber, K. M., Rdiger, S., Kruska, L.,
Krahn, T. and Kramer, F. 2010. Circulating biomarkers of
tissue remodelling in pulmonary hypertension. Biomarkers. 15:
523–532.
97.
Sedighi, M., Nazari, A., Faghihi, M., Rafieian -Kopaei, M.,
Karimi, A., Moghimian, M., Mozaffarpur, S. A., Rashidipour,
M., Namdari, M., Cheraghi, M. and Rasoulian, B. 2018.
Protective effects of cinnamon bark extract against ischemia reperfusion injury and arrhythmias in rat. Phyther. Res. 32:
1983–1991.
98.
Seropian, I. M., Toldo, S., Van Tassell, B. W. and Abbate, A.
2014. Anti-inflammatory strategies for ventricular remodeling
following ST-segment elevation acute myocardial infarction. J.
Am. Coll. Cardiol. 63: 1593–1603.
99.
Sezai, A. and Takayama, T. 2020. Role of the university
hospital as a regional liaison center in preparation for the
heart failure pandemic. J. Nihon Univ. Med. Assoc. 79: 241–
245.
100. Shimamura, N., Matchett, G., Yatsushige, H., Calvert, J. W.,
Ohkuma, H. and Zhang, J. 2006. Inhibition of integrin v3
189
ameliorates focal cerebral ischemic damage in the rat middle
cerebral artery occlusion model. Stroke. 37: 1902–1909.
101. Shimokawa, H., Miura, M., Nochioka, K. and Sakata, Y. 2015.
Heart failure as a general pandemic in Asia. Eur. J. Heart
Fail. 17: 884–892.
102. Shinde, A. V and Frangogiannis, N. G. 2014. Fibroblasts in
myocardial infarction: A role in inflammation and repair. J.
Mol. Cell. Cardiol. 70: 74–82.
103. Skuli, N., Monferran, S., Delmas, C., Favre, G., Bonnet, J.,
Toulas, C. and Moyal, E. C. J. 2009. v3/v5 integrins-FAKRhoB: A novel pathway for hypoxia regulation in
glioblastoma. Cancer Res. 69: 3308–3316.
104. Sonbol, H. S. 2018. Extracellular matrix remodeling in human
disease. J. Microsc. Ultrastruct. 6: 123–128.
105. Sovari, A. A. 2016. Cellular and molecular mechanisms of
arrhythmia by oxidative stress. Cardiol. Res. Pract. 2016:
9656078.
106. Steubl, D., Kumar, S. V., Tato, M., Mulay, S. R., Larsson, A.,
Lind, L., Risérus, U., Renders, L., Heemann, U., Carlsson, A.
C., Ärnlöv, J. and Anders, H. J. 2017. Circulating cathepsin-S
levels correlate with GFR decline and sTNFR1 and sTNFR2
levels in mice and humans. Sci. Rep. 7: 43538.
107. Sugden, P. H. 1999. Signaling in myocardial hypertrophy: life
after calcineurin? Circ. Res. 84: 633–646.
190
108. Sugiyama, A., Ito, R., Okada, M. and Yamawaki, H. 2020.
Long-term administration of recombinant canstatin prevents
adverse cardiac remodeling after myocardial infarction. Sci.
Rep. 10: 12881.
109. Sugiyama, A., Kaisho, M., Okada, M., Otani, K. and
Yamawaki, H. 2020. Decreased expression of canstatin in rat
model of monocrotaline-induced pulmonary arterial
hypertension: Protective effect of canstatin on right
ventricular remodeling. Int. J. Mol. Sci. 21: 6797.
110. Sugiyama, A., Mitsui, A., Okada, M. and Yamawaki, H. 201 9.
Cathepsin S degrades arresten and canstatin in infarcted area
after myocardial infarction in rats. J. Vet. Med. Sci. 81: 522–
531.
111. Sugiyama, A., Okada, M. and Yamawaki, H. 2017.
Pathophysiological roles of canstatin on myofibroblasts after
myocardial infarction in rats. Eur. J. Pharmacol. 807: 32–43.
112. Sugiyama, A., Okada, M. and Yamawaki, H. 2020. Canstatin
suppresses isoproterenol-induced cardiac hypertrophy through
inhibition of calcineurin/nuclear factor of activated T -cells
pathway in rats. Eur. J. Pharmacol. 871: 172849.
113. Sun, F., Lu, Z., Zhang, Y., Geng, S., Xu, M., Xu, L., Huang,
Y., Zhuang, P. and Zhang, Y. 2018. Stage -dependent changes
of 2-adrenergic receptor signaling in right ventricular
remodeling in monocrotaline-induced pulmonary arterial
191
hypertension. Int. J. Mol. Med. 41: 2493–2504.
114. Sun, H. and Wang, Y. 2012. Prostaglandin E2 in remote control
of myocardial remodeling. Circulation. 125: 2818–2820.
115. Takii, T., Yasuda, S., Takahashi, J., Ito, K., Shiba, N.,
Shirato, K. and Shimokawa, H. 2010. Trends in ac ute
myocardial infarction incidence and mortality over 30 years in
Japan: Report from the MIYAGI-AMI registry study. Circ. J.
74: 93–100.
116. Talman, V. and Ruskoaho, H. 2016. Cardiac fibrosis in
myocardial infarction-from repair and remodeling to
regeneration. Cell Tissue Res. 365: 568–581.
117. Tello, K., Seeger, W., Naeije, R., Vanderpool, R., Ghofrani,
H. A., Richter, M., Tedford, R. J. and Bogaard, H. J. 2021.
Right heart failure in pulmonary hypertension: Diagnosis and
new perspectives on vascular and direct right ventricular
treatment. Br. J. Pharmacol. 178: 90–107.
118. 筒 井
裕之
班 長 [合 同 研 究 班 参 加 学 会 ・ 研 究 班 (日 本 循 環 器 学
会、日本心不全学会、日本胸部外科学会、日本高血圧学
会、日本心エコー図学会、日本心臓血管外科学会、日本心
臓病学会、日本心臓リハビリテーション学会、日本超音波
医学会、日本糖尿病学会、日本不整脈心電学会、厚生労働
省
難治性疾患政策研究事業「特発性心筋症に関する調査研
究」研究班、日本医療研究開発機構
難治性疾患実用化研究
事業「拡張相肥大心筋症を対象とした多施設登録観察研
192
究 」 研 究 班 )報 告 ] 2018. 急 性 ・ 慢 性 心 不 全 診 療 ガ イ ド ラ イ ン
(2017年 改 訂 版 ).
119. Turner, N. A. and Porter, K. E. 2013. Function and fate of
myofibroblasts after myocardial infarction. Fibrogenesis
Tissue Repair. 6: 5.
120. Valiente-Alandi, I., Schafer, A. E. and Blaxall, B. C. 2016.
Extracellular matrix-mediated cellular communication in the
heart. J. Mol. Cell. Cardiol. 91: 228–237.
121. van de Veerdonk, M. C., Bogaard, H. J. and Voelkel, N. F.
2016. The right ventricle and pulmonary hypertension. Heart
Fail. Rev. 21: 259–271.
122. Vonk-Noordegraaf, A., Haddad, F., Chin, K. M., Forfia, P. R.,
Kawut, S. M., Lumens, J., Naeije, R., Newman, J., Oudiz, R.
J., Provencher, S., Torbicki, A., Voelkel, N. F. and Hassoun,
P. M. 2013. Right heart adaptation to pulmonary arterial
hypertension: Physiology and pathobiology. J. Am. Coll.
Cardiol. 62: D22–D33.
123. Wang, B., Sun, J., Kitamoto, S., Yang, M., Grubb, A.,
Chapman, H. A., Kalluri, R. and Shi, G. P. 2006. Cathepsin S
controls angiogenesis and tumor growth via matrix -derived
angiogenic factors. J. Biol. Chem. 281: 6020–6029.
124. Wang, Y., Li, C., Shi, L., Chen, X., Cui, C., Huang, J., Chen,
B., Hall, D. D., Pan, Z., Lu, M., Hong, J., Song, L. S. and
Zhao, S. 2020. Integrin 1D deficiency-mediated RyR2
193
dysfunction contributes to catecholamine -sensitive ventricular
tachycardia in arrhythmogenic right ventricular
cardiomyopathy. Circulation. 141: 1477–1493.
125. Watanabe, T., Kusachi, S., Yamanishi, A., Kumashiro, H.,
Nunoyama, H., Sano, I., Nakahama, M., Murakami, T., Naito,
I., Ninomiya, Y. and Tsuji, T. ...
論文の公開元へ
